India must focus on the sectors in which India has competitive edge over other countries and address the problems faced by the various stakeholders so that country’s exports can grow. This was stated by Union Minister of Commerce and Industry, Shri Piyush Goyal at the review meeting on Production Linked Incentive Scheme, one of the notable initiatives for making India “Aatmanirbhar’ in the manufacturing sector.

Shri Goyal urged the need for becoming self-reliant in the key sectors covered under the PLI Scheme. Emphasizing that the Ministries should focus on creating quality skilled manpower instead of focusing on the quantity and resolve infrastructure bottlenecks in collaboration with NICDC, Shri Goyal stressed on preparing a roadmap for the next five years both on investment and disbursement.

The meeting was attended by all the concerned Ministries.

The PLI Scheme is under various stages of implementation in 14 key sectors. The scheme has witnessed investments worth Rs. 1.76 lakh crores, which has generated production/ sales of over Rs. 16.5 lakh crore and employment of over 12 lakhs (Direct & Indirect) till March 2025. Cumulative incentive amount of Rs. 21,534 crore has been disbursed under PLI Schemes for 12 Sectors viz. Large-Scale Electronics Manufacturing (LSEM), IT Hardware, Bulk Drugs, Medical Devices, Pharmaceuticals, Telecom & Networking Products, Food Processing, White Goods, Automobiles & Auto components, Specialty Steel, Textiles and Drones & Drone Components.

The impact of PLI Schemes has been significant across various sectors in India. These schemes have incentivized domestic manufacturing, leading to increased production, job creation and a boost in exports. Some of the notable sectors are as follows:

The PLI Scheme for Bulk Drugs aims to boost domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs) in India. The scheme has contributed to India becoming a net exporter of bulk drugs (2280 cr.) from net importer (-1930 cr.) as was the case in FY 2021-22. It has also resulted in significant reduction in gap between the domestic manufacturing capacity and demand of critical drugs.

***

Abhishek Dayal/ Abhijith Narayanan

Pli Press Release